290 related articles for article (PubMed ID: 34508101)
21. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
22. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
[TBL] [Abstract][Full Text] [Related]
23. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
24. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
25. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
26. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice.
Jiang S; Minter LC; Stratton SA; Yang P; Abbas HA; Akdemir ZC; Pant V; Post S; Gagea M; Lee RG; Lozano G; Barton MC
J Hepatol; 2015 Feb; 62(2):371-9. PubMed ID: 25281858
[TBL] [Abstract][Full Text] [Related]
27. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells.
Kai K; Iwamoto T; Kobayashi T; Arima Y; Takamoto Y; Ohnishi N; Bartholomeusz C; Horii R; Akiyama F; Hortobagyi GN; Pusztai L; Saya H; Ueno NT
Oncogene; 2014 Jan; 33(4):440-8. PubMed ID: 23376849
[TBL] [Abstract][Full Text] [Related]
28. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
29. Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway.
Chen J; Zhou Z; Yao Y; Dai J; Zhou D; Wang L; Zhang QQ
J Cell Mol Med; 2018 Oct; 22(10):4760-4770. PubMed ID: 30010249
[TBL] [Abstract][Full Text] [Related]
30. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
[TBL] [Abstract][Full Text] [Related]
31. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract][Full Text] [Related]
32. The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis.
Wang A; Arantes S; Yan L; Kiguchi K; McArthur MJ; Sahin A; Thames HD; Aldaz CM; Macleod MC
BMC Cancer; 2008 Sep; 8():268. PubMed ID: 18808719
[TBL] [Abstract][Full Text] [Related]
33. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterizations of Nop16 in murine mammary tumors with varying levels of c-Myc.
Kundel DW; Stromquist E; Greene AL; Zhdankin O; Regal RR; Rose-Hellekant TA
Transgenic Res; 2012 Apr; 21(2):393-406. PubMed ID: 21863248
[TBL] [Abstract][Full Text] [Related]
35. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.
Liu H; Murphy CJ; Karreth FA; Emdal KB; White FM; Elemento O; Toker A; Wulf GM; Cantley LC
Cancer Discov; 2018 Mar; 8(3):354-369. PubMed ID: 29203461
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer.
Chambon M; Orsetti B; Berthe ML; Bascoul-Mollevi C; Rodriguez C; Duong V; Gleizes M; Thénot S; Bibeau F; Theillet C; Cavaillès V
Am J Pathol; 2011 Apr; 178(4):1461-9. PubMed ID: 21435435
[TBL] [Abstract][Full Text] [Related]
37. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
38. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
40. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
